1. US Food and Drug Administration. FDA approves neoadjuvant/ adjuvant pembrolizumab for resectable non-small cell lung cancer. fda.gov, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neoadjuvant-adjuvant-pembrolizumab-resectable-non-small-cell-lung-cancer (2023).
2. US Food and Drug Administration. FDA approves neoadjuvant nivolumab and platinum-doublet chemotherapy for early-stage non-small cell lung cancer. fda.gov, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neoadjuvant-nivolumab-and-platinum-doublet-chemotherapy-early-stage-non-small-cell-lung (2022).
3. Strohbehn, G. W., Kacew, A. J., Goldstein, D. A., Feldman, R. C. & Ratain, M. J. Combination therapy patents: a new front in evergreening. Nat. Biotechnol. 39, 1504–1510 (2021).
4. Theoret, M. Selected regulatory considerations for cancer immunotherapeutic combinations: contribution of individual components to effect of combination. nationalacademies.org, https://www.nationalacademies.org/documents/embed/link/LF2255DA3DD1C41C0A42D3BEF0989ACAECE3053A6A9B/file/DB9638AC5DA89CA34A0EF877A87AFF4EFFE659FF9F3C?noSaveAs=1 (accessed 14 December 2023).
5. Eun, Y. et al. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Sci. Rep. 9, 14039 (2019).